1. Immunology/Inflammation
  2. NO Synthase
    COX
  3. Prim-O-glucosylcimifugin

Prim-O-glucosylcimifugin 

Cat. No.: HY-N0635 Purity: 99.76%
Handling Instructions

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

For research use only. We do not sell to patients.

Prim-O-glucosylcimifugin Chemical Structure

Prim-O-glucosylcimifugin Chemical Structure

CAS No. : 80681-45-4

Size Price Stock Quantity
10 mM * 1  mL in DMSO USD 165 In-stock
Estimated Time of Arrival: December 31
5 mg USD 150 In-stock
Estimated Time of Arrival: December 31
10 mg USD 270 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE Prim-O-glucosylcimifugin

    Prim-O-glucosylcimifugin purchased from MCE. Usage Cited in: Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384.

    RAW 264.7 cells are treated with Lipopolysaccharide (1 μg/mL) and various concentrations of prim-O-glucosylcimifugin (15, 50 and 100 μg/mL) and harvest at 4 h posttreatment. Cells treated with DMSO are set as control. p-JAK2, JAK2, p-STAT3, and STAT3 are detected by Western blotting.

    View All COX Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

    IC50 & Target[1]

    iNOS

     

    COX-2

     

    In Vitro

    Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/mL) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/mL Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/mL) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner[1].

    In Vivo

    Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01)[1].

    Molecular Weight

    468.45

    Formula

    C₂₂H₂₈O₁₁

    CAS No.

    80681-45-4

    SMILES

    COC1=C(C[[email protected]@H](C(C)(O)C)O2)C2=CC(OC(CO[[email protected]@H]([[email protected]@H]([[email protected]@H](O)[[email protected]@H]3O)O)O[[email protected]@H]3CO)=C4)=C1C4=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 150 mg/mL (320.20 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1347 mL 10.6735 mL 21.3470 mL
    5 mM 0.4269 mL 2.1347 mL 4.2694 mL
    10 mM 0.2135 mL 1.0673 mL 2.1347 mL
    *Please refer to the solubility information to select the appropriate solvent.
    References
    Cell Assay
    [1]

    Cell Counting Kit (CCK-8) is used to determine the cytotoxic concentrations of Prim-O-glucosylcimifugin. In brief, the Raw 264.7 cells are plated at a density of 1×104 cells per well in a 96-well and incubated overnight. Cells are then stimulated with 1 μg/mL LPS and treated with various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL; MedChem Express, Princeton, NJ, USA) or DMSO. After incubation at 37°C for 24 h, CCK-8 solution is added to each well and incubated for another 1 h. The absorbance is measured at 450 nm using a microplate reader[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    BALB/c male mice, 8 weeks old and weighing approximately 18 to 20 g, are used. The mice are randomly divided into five groups: Control group; LPS group; LPS+Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg bodyweight). Prime-O-glucosylcimifugin is given intraperitoneally. One hour later, LPS group and LPS+Prime-O-glucosylcimifugin group mice are given 50 μL LPS intranasally (i.n) (200 mg/L) to induce acute lung injury. Control mice are given 50 μL PBS intranasally (i.n) without LPS[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Purity: 99.76%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    Prim-O-glucosylcimifuginNO SynthaseCOXNitric oxide synthasesNOSCyclooxygenaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Prim-O-glucosylcimifugin
    Cat. No.:
    HY-N0635
    Quantity:
    MCE Japan Authorized Agent: